Hila Pharma is developing products for molecular imaging that will allow precise diagnoses and improved therapy planning. Its main profits come from the field of nuclear medicine, for which the company trades a broad range of products, aimed at both diagnostic and therapeutic purposes. Hila Pharma is capable of supplying any type of the SPECT range of diagnostic products, PET diagnostic products, MRI contrast agents, and several nuclear therapeutic materials, such as LU-177.